No abstract

Introducción: El objetivo de este trabajo es profundizar en el conocimiento de la enfermedad periimplantaria y los tratamientos existentes descritos en la literatura. Material y método: Revisión bibliográfica de las enfermedades periimplantarias, basada en una búsqueda en bases de datos Pubmed, Medline y Cochrane Library, utilizando como palabras clave "periimplantitis, mucositis, tabaquism, oral microbiota, occlusal overload, surgical treatment, antimicrobial therapy, detoxification, regenerative therapy, bone defects". Desarrollo y discusión: Análisis de los factores de riesgo, el diagnóstico y el tratamiento de las enfermedades periimplantarias. Conclusiones: Los factores como el tabaco o una historia de periodontitis, junto con una mala higiene oral, son las principales causas de las enfermedades periimplantarias. Un correcto diagnóstico de la etiología, así como, la adecuada elección de la terapéutica, pueden detener el avance de la enfermedad periimplantaria. Tras el tratamiento realizado, será muy importante el control periódico y el mantenimiento de una correcta higiene oral.

comparative study of furazolidone and placebo in addition to oral rehydration in the treatment of acute infantile diarrhea. Scand J Gastroenterol 1989,24(suppl 169), 39-46Between July and October 1987 an outpatient study of 191 children with acute diarrhea was undertaken in two rural communities in Mexico. Through a double-blind randomization we compared the efficacy of a combination therapy of furazolidone, 7.5 mg/kg/day, plus standard oral rehydration therapy (ORT) (96 patients) versus a placebo plus ORT (95 patients), each given for 5 days. Diarrheal stool samples were collected from all patients before therapy. By means of a two-vial transport media system the samples were sent to a university laboratory and examined for viral, bacterial, and parasitic organisms. The most commonly isolated organisms were enterotoxigenic Escherichia coli (13%) and Giardia lamblia (13%). Patients who received furazolidone plus ORT showed a greater reduction in duration of diarrhea when compared with those receiving placebo plus ORT (63.4 h versus 71.44 h). There was also a trend toward shorter duration of diarrhea in patients with Giardia who were treated with furazolidone/ORT compared with Giardia patients in the placebo/ ORT group. When fecal leukocytes were present in the stool, the furazolidone/ORTtreated patients had a significantly higher percentage of clinical cures (79% versus 54%, p = 0.03) and an overall shorter duration of diarrhea (62.0 h versus 80.6 h, p = 0.055) at the end of 5 days of therapy than did the placebo/ORT-treated group.